Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339387 · ClinicalTrials.gov registry record
COVID-19 Risk Stratification
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 1,326
- Enrollment target
NCT04339387: Completed study, sponsored by Brigham and Women's Hospital.
NCT04339387 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,326 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04339387 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 1,326 participants
- Enrollment target
Study Summary
The investigators seek to derive and validate a clinically useful risk score for patients with Coronavirus Disease 2019 to aide clinicians in the safe discharge of patients.
Primary Outcome
Patient with COVID-19 who does not require supplemental oxygen, does not require intensive care unit-level care, and does not die.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,326 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2020-04-26 |
What the finished NCT04339387 record still lists
NCT04339387 is an observational study that tracks outcomes without assigning an intervention. Its 1,326 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04339387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04339387 about?
NCT04339387 is a clinical study titled "COVID-19 Risk Stratification". The investigators seek to derive and validate a clinically useful risk score for patients with Coronavirus Disease 2019 to aide clinicians in the safe discharge of patients.
What is the current status of trial NCT04339387?
This trial is currently completed. The enrollment target is 1,326 participants. The study started on 2020-03-01. Estimated completion is 2020-04-26.
Who is sponsoring clinical trial NCT04339387?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05889182 · 1,328 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI